TAMPA, Fla.–(BUSINESS WIRE)–PanGenex Corporation (Pink Sheets: PGXC) announces the product launch of LIPIDEME™, an all-natural nutraceutical formulated with scientifically proven ingredients and the first product on the market to combine the triglyceride-lowering power of Omega-3 fatty acids with the cholesterol lowering ability of phytosterols and tocotrienols – plus the free-radical fighting capacity of Coenzyme Q10 (CoQ10).
Dr. Eric J. Springer, Chiropractic Physician with Northeast Chiropractic states that “LIPIDEME is one of the most exciting products out there today. LIPIDEME is an easy and effective way to help reduce cholesterol and improve cardiovascular health. As a Physician I look for the highest quality when recommending products to my patients. I’ve experienced the results of LIPIDEME personally and they speak for themselves. LIPIDEME is the gold standard in natural cholesterol lowering supplements.”
LIPIDEME is formulated with pharmaceutical grade fish oil that is over 86% pure Omega-3s; the highest content available without a prescription for heart, mental, joint and skin health. The Omega-3s in LIPIDEME are molecularly distilled and tested to ensure that there are no detectable levels of Mercury, PCBs, or other toxins or heavy metals. The US Food and Drug Administration and the American Heart Association all recommend the consumption of Omega-3 fatty acids from fish, and state that Omega-3s provide much needed protection for your heart.
LIPIDEME provides the proper amount of phytosterols to assist in naturally lowering the amount of cholesterol that is absorbed through food. Phytosterols are natural, plant derived compounds that when taken in appropriate amounts, block the absorption of cholesterol from food. Phytosterol administration has been proven to result in lower serum levels of bad cholesterol (LDL), yet show no reduction in good cholesterol, (HDL).
LIPIDEME contains tocotrienols, part of the vitamin E family, which are a 40-60 time more potent antioxidant than the common form of vitamin E, tocopherol. Research shows that delta and gamma tocotrienols inhibit cholesterol production in the liver. Tocotrienols do not effect liver health or rob the body of CoQ10.
LIPIDEME in formulated with CoQ10 which has been the subject of thousands of clinical trials and has been shown to be a potent antioxidant and to boost energy, especially in cardiac muscle tissue.
LIPIDEME can be purchased through the Internet at www.PanGenex.com. LIPIDEME is also commercially available through qualified practitioners across the country with new practitioners ordering the product daily. PanGenex anticipates practitioners, distributors and retail sales to increase as LIPIDEME is launched throughout the country.
(1) The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Learn More about Dr. Eric Springer at:
About PanGenex Corporation:
PanGenex is a publicly traded corporation (PINK SHEETS: PGXC) and pursues business opportunities in the $60 billion dollar nutraceutical and dietary supplement industry. With a focus specifically on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions throughout the population. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners throughout the U.S., fine retail establishments and the internet on websites such as www.PanGenex.com and www.Calgenex.com.
CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements,” which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks” or “will.” Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook.